Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
The Apheresis Unit, established in 1980, and which recently opened a new room, has achieved this milestone for the first time since its creation.
The Joan Rodés-Josep Baselga Advanced Research Contracts in Oncology and Neurodegenerative Diseases, awarded by the BBVA Foundation and Hospital Clín1
A study led by researchers from the Hospital Clínic-IDIBAPS shows that a new treatment without chemotherapy is effective in treating indolent clinica1
We speak to Dr. Mertixell Mollà, head of the Radiation Oncology Service and coordinator of the Hospital Clínic Cancer Technical Committee, about the1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, resu1
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organization1
